‘Ebola is real’: Uganda to trial vaccines and shut schools early to contain outbreak READ MORE: Ebola: The World of Panic
This time, there will be a way for healthcare workers who are exposed to Ebola to keep themselves from infecting other healthcare workers and the patients they treat.
The company, CVC Biomedical, will partner with the Center for Disease Control (CDC) and the University of Maryland to create an Ebola vaccine called, “EbolaRibua,” which they have scheduled to be tested on humans in late August.
The vaccine, which has already been selected by the Ugandan government, is based on the genetic sequence of the virus that causes Ebola.
The trial will be the second time the vaccine has been tested on humans.
This time, the vaccine will be administered by a doctor in Uganda called Anthony Muyaba.
Dr. Muyaba, who is a specialist in infectious diseases at the National Hospital for Tropical Diseases, is the son of Dr. Anthony Muyaba, who was killed by Ebola at the height of the epidemic.
He has been the director of the hospital for two years. It is a government and mission hospital in the country’s capital, Kampala. And it is one of the few remaining Ebola treatment centers in the world.
Dr. Muyaba is also the co-founder of a company that produces the Ebola vaccine called, “Kinsa Pharmaceutical.”
The vaccine is made in Kinsa and sent to the CDC.
According to a press release, Dr. Muyaba “explained that the vaccine will be given, in conjunction with the drugs used to treat patients, to the patients who cannot be cured by other means. These drugs will not work on patients who are fully protected from the disease by vaccination.”
The statement noted that during the first year of the vaccine’s testing, there was “little evidence that Kinsa RIX-121 [the vaccine] was less effective in protecting healthy adults than the licensed live, attenuated virus,” so Dr. Muyaba has decided to continue testing the vaccine on humans.
The CDC said it is currently planning to enroll 500 healthy adults between 18 and 45 years old to undergo the first phase of the vaccine trial.
There are three conditions that must be met in order
